Kailera Therapeutics, Inc. Common Stock (KLRA)

Kailera Therapeutics, Inc. Common Stock (KLRA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.7B; returns 1 day -3.2%, 1 week +14.2%.

Kailera Therapeutics is a late-stage clinical biotechnology company focused on developing a diversified portfolio of GLP-1 (glucagon-like peptide-1) based therapies for obesity and metabolic disorders. As of April 2026, the company operates as a pre-revenue entity, following a record-breaking $625 million upsized IPO in April 2026.

Groups KLRA belongs to

• Biotechnology
• Recent IPOs
• GLP-1 Agonists
• Weight Management
• Clinical Stage Biotech
• Metabolic Disorders
• Healthcare
• Clinical Stage
• Biopharmaceutical
• Pharmaceuticals
• Unmet Medical Needs

KLRA financial model: income statement, cash flow and balance sheet